Replies to post #7514 on Sorrento Therapeutics Inc (SRNE)

[1776club]

I am right with you. Sorrento has a High potenrial but is only selling one product that might pay the waterbill and cable. Hard cold facts is that they have 133 pattents of which 36 have been granted since 2013-12-05 and several added companies adding to overhead. Lots of programs ( 22) in 4 portfolios of which none are in production adding to cashflow. Maybe 100 million shares waiting to be added to the 260M being played with. That is where they are Today. 2021 is the year for Sorrento with 2022 and 2023 adding value...IF they receive FDA approval. There are thousands of programs that have been put aside due to COVID and will flood the zone once COVID is on the downside but the window is closing and Sorrento has to get approvels by mid year on a meaningful number of COVID programs or they could be in for a long dry spell. I believe STI 2020 COVI-AMG™, Covi-STIX, COVI-DROPS STI 2099 will be approved H1 2021 and a good shot for ABIVERTINIB STI 5656 also. I do not plan on selling soon but will over a period of years depending on tax code...not until late 2021 or 2022.
It would be nice to know what the plan for SALICYN-30 Anti-viral – STI 2030 is. The company has value but the marketplace determines that value and quite frankly the marketplace by this time next year...

[dia76ca]

All I want for Christmas is for one analyst, ANY analyst, to do a serious, comprehensive analysis of Sorrento's entire pipeline! The most recent ignored the $34 million DARPA grant! This opens the door to further DOD and Warpspeed funding...it is big deal!
It also excluded any value to Covi-Drops or SmartPharm applications to Covid or cancer applications. It doesn't mention SP-102 for sciatic pain (phase 3 enrollment complete this month) and excluded any value from RTX for cancer pain. It doesn't refer to the potential ACEA acquisition or assign any value to the Abivirtinib phase 3 NSCLC application. And there is no value assigned to Celularity or to the potential $1 billion PSS lawsuit settlement. It also applied very conservative discount rates.

Maybe 2021 will see some analysts do some serious work...until then their average target of $25 will remain, but I would not be surprised to see that exceeded in January. All that is needed is two or three good EUA approvals! Merry Christmas and a Happy and Healthy New Year to all!